Abstract
Diaziquone (AZQ) is a lipid soluble alkylating agent which was designed for increased CNS penetration. Its principle toxicity is myelosuppression. We conducted a phase I trial using AZQ in combination with GM-CSF to determine if the maximal tolerate dose (MTD) of AZQ could be escalated. Using GM-CSF on a standard schedule, we were unable to escalate the previously determined MTD of diaziquone with the use of this colony stimulating factor.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / blood
-
Antineoplastic Agents / pharmacokinetics*
-
Antineoplastic Agents / therapeutic use
-
Aziridines / administration & dosage
-
Aziridines / blood
-
Aziridines / pharmacokinetics*
-
Aziridines / therapeutic use
-
Benzoquinones / administration & dosage
-
Benzoquinones / blood
-
Benzoquinones / pharmacokinetics*
-
Benzoquinones / therapeutic use
-
Blood Platelets / drug effects
-
Bone Marrow / drug effects*
-
Colorectal Neoplasms / drug therapy
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Drugs, Investigational / administration & dosage
-
Drugs, Investigational / pharmacokinetics*
-
Drugs, Investigational / therapeutic use
-
Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
-
Granulocyte-Macrophage Colony-Stimulating Factor / blood
-
Granulocyte-Macrophage Colony-Stimulating Factor / pharmacokinetics*
-
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
-
Humans
-
Infusions, Intravenous
-
Injections, Subcutaneous
-
Melanoma / drug therapy
-
Neutrophils / drug effects
Substances
-
Antineoplastic Agents
-
Aziridines
-
Benzoquinones
-
Drugs, Investigational
-
Granulocyte-Macrophage Colony-Stimulating Factor
-
diaziquone